Evidence map›Paper›PMID 41519737›Full record

ArticleBMC nephrology2026

Use of hydroxychloroquine to treat patients with IgA nephropathy and time to accelerated glucocorticoid tapering.

Mingming Ma, Qiao Luo, Meifen Huang, Liangmei Chen, Wenxue Liang, Yingxue Zhong, Fanna Liu, Baozhang Guan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mingming Ma *Institute of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Qiao Luo *Institute of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Meifen Huang *Institute of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Liangmei ChenInstitute of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Wenxue LiangInstitute of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Yingxue ZhongInstitute of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China. Zhong_Yingxue@163.com.
Fanna LiuInstitute of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China. tliufana@jnu.edu.cn.
Baozhang GuanInstitute of Nephrology and Blood Purification, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China. guanbaozhang130@163.com.

Funding

Basic and Applied Basic Research Foundation of the Guangzhou Municipal-University Joint Funding Program No. 202201020068Guangzhou Science and Technology Plan Project No. 2023A03J1011
6 · The paper itself

Abstract

backgroundHydroxychloroquine (HCQ) has shown potential in reducing proteinuria in IgA nephropathy (IgAN) and may facilitate glucocorticoid (GC) tapering, but its efficacy remains understudied.

methodsIn this retrospective cohort study, we analyzed 75 biopsy-confirmed IgAN patients treated with HCQ plus GC and 75 propensity score-matched controls receiving GC-only (2014–2023). The primary outcome was time to GC dose reduction to ≤ 5 mg/day within 6 months, with end-stage renal disease (ESRD) as a competing risk. Secondary outcomes included renal prognosis (eGFR decline, proteinuria). A Fine-Gray competing risk model assessed the association between HCQ and time to GC dose reduction (≤ 5 mg/day), with end-stage renal disease as a competing event.

resultsHCQ significantly increased the probability of tapering success (adjusted HR = 1.68, 95% CI: 1.08–2.61). The HCQ + GC group also showed improved renal outcomes, with reduced proteinuria (median reduction: 72.2% vs. 49.9%, p = 0.01).

conclusionHCQ accelerates GC tapering in IgAN, offering a potential steroid-sparing strategy. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Drug TaperingGlomerulonephritis, IGAGlucocorticoidsHydroxychloroquineAdultDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansKidney Failure, ChronicMaleMiddle AgedProteinuriaRetrospective StudiesTime FactorsTreatment OutcomeGlucocorticoidsHydroxychloroquineGlucocorticoidGlucocorticoid reductionHydroxychloroquineIgA nephropathyPropensity score matching

Identifiers

PMID41519737
PMCPMC12882212

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.